医学
浆液性液体
卵巢癌
回顾性队列研究
阶段(地层学)
怀孕
浆液性囊腺癌
生育率
疾病
外科
妇科
内科学
癌症
人口
古生物学
环境卫生
生物
遗传学
作者
Francesca Falcone,Enrico Breda,Gabriella Ferrandina,Mario Malzoni,Anna Myriam Perrone,Gennaro Cormio,Violante Di Donato,Luigi Frigerio,Giorgia Mangili,Francesco Raspagliesi,Anna Festi,Giuseppe Scibilia,Nicoletta Biglia,Roberto Sorio,Enrico Vizza,Simona Losito,Stefano Greggi
标识
DOI:10.1016/j.ygyno.2021.03.023
摘要
To evaluate oncological and reproductive outcomes of women undergoing fertility-sparing surgery (FSS) for stage II-III serous borderline ovarian tumors (BOTs).A multi-institutional retrospective study was conducted within the MITO Group.A total of 91 patients were recruited. The median follow-up time from primary cytoreduction was 127 months (IQR range 91-179). Forty-nine patients (53.8%) experienced at least one recurrence (median time to first relapse 22 months, IQR range 9.5-57). At univariable analysis, significant predictors of relapse were: size of largest extra-ovarian lesion, peritoneal cancer index, completeness of cytoreduction, type of implants. After multivariable analysis, the size of extra-ovarian lesions and the presence of invasive implants resulted as the only independent predictors of recurrence. Median disease-free survival (DFS) was 96 months (95% CI, 24.6-167.3), while median disease-specific survival (DSS) was not reached. Twenty-nine patients (31.8%) attempted to conceive: 20 (68.9%) achieved at least one pregnancy and 18 (62%) gave birth to a healthy child. At the end of the observation period, 88 patients (96.7%) showed no evidence of disease, 2 (2.2%) were alive with disease, and 1 patient (1.1%) died from BOT.Despite the recurrence high rate, FSS provides good chances of reproductive success with no impact on DSS. The presence of invasive peritoneal implants affects the DFS but not DSS nor reproductive outcome. The risk of recurrence would not seem to be related to the ovarian preservation per se, but to the natural history of the initial peritoneal spread.
科研通智能强力驱动
Strongly Powered by AbleSci AI